van Esbroeck ACM, Varga ZV, Di X, van Rooden EJ, Toth VE, Onodi Z, Kusmierczyk M, Leszek P, Ferdinandy P, Hankemeier T, van der Stelt M and Pacher P

Pharmacol Res (2020) 151: 104578

Link to abstract

Acute myocardial infarction and subsequent post-infarction heart failure are among the leading causes of mortality worldwide. The endocannabinoid system has emerged as an important modulator of cardiovascular disease, however the role of endocannabinoid metabolic enzymes in heart failure is still elusive. Herein, we investigated the endocannabinoids and their metabolic enzymes in ischemic end-stage failing human hearts and non-failing controls.